ArticleFrontiers in medicine2021
The Assessment of the Innovativeness of a New Medicine in Italy.
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Closing the first wave of drug innovativeness in italy: final evidence from 2017 to 2025.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Assessment and Appraisal of Drug Innovativeness in Italy: Ultimate Evidence on Key Drivers and Consistency.Journal of market access & health policy · 2026Article
- The Italian Assessment System for Innovative Medicines: An 8-Year Retrospective Analysis of Outcomes, Criteria, Timelines and Funding Dynamics.Applied health economics and health policy · 2026Article
- The Pharmaceutical Innovativeness Index: Supporting Value-Based Economic Regulation of Innovative Medicines.Journal of market access & health policy · 2025Article
- Establishing a Dedicated Fund to Improve Patient Access to Cancer Medicines: Key Considerations and Policy Implications for Thailand Comment on "Scoping Review of International Experience of a Dedicated Fund to Support Patient Access to Cancer Drugs: Policy Implications for Thailand".International journal of health policy and management · 2025Article
- From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy.PharmacoEconomics - open · 2024Article
- Do France, Germany, and Italy agree on the added therapeutic value of medicines?International journal of technology assessment in health care · 2023Article
- The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency.PharmacoEconomics - open · 2023Article
- Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies.Frontiers in medical technology · 2022Article
- Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.